


Improving Surgical Wound Healing



In a prospective randomized and double-blind clinical trial of GI cancer surgery patients, those who received IMPACT® formula had no wound healing complications, as compared to a 27% incidence in those receiving standard nutrition.⁶

Study Objective: To assess the effect of early postoperative enteral immunonutrition (IM) on the wound healing process in patients undergoing surgery for gastric cancer ($n=60$).

Synopsis:

- After 7 days of early postoperative feeding, analysis showed no wound healing complications in the IM group and a rate of 27% in the control group (isonitrogenous/isocaloric standard formula).
- Higher hydroxyproline levels were measured postoperatively in the IM group vs. the control group (59.7 nmol/cm vs. 28.0 nmol/cm, $p=0.0018$).
 - An inverse trend was also shown between hydroxyproline levels and wound healing complications of the abdominal wall ($p=0.058$).
- Incidence of infectious complications was 6.7% (IM) vs. 30% (control), and incidence of surgical wound infection was 3.3% (IM) vs. 13.3% (control).
- Mean length of hospital stay (LOS) was 2 days shorter in the IM group vs. control ($p=0.02$).

Postoperative Complications	Study group (n = 30)	Control group (n = 30)	P
Wound healing complications	0	8 (26.7%)	0.005
Dehiscence	0	2 (6.7%)	ns
Evisceration	0	1 (3.3%)	ns
Suture failure	0	5 (16.6%)	0.03
Infectious complications	2 (6.7%)	9 (30%)	0.01
Surgical wound infection	1 (3.3%)	4 (13.3%)	ns
Intraabdominal abscess	0	1 (3.3%)	ns
Sepsis	0	0	
Pneumonia	0	2 (6.7%)	ns
Urinary tract infection	1 (3.3%)	2 (6.7%)	ns
Global complications	4 (13.3%)	13 (43.3%)	0.01
Mortality	1 (3.3%)	2 (6.7%)	ns

Adapted from Ferreras et al., 2005, Table 5

IMPROVING SURGICAL OUTCOMES WITH

IMPACT® Immunonutrition Formulas

Contains a unique blend of arginine, omega-3 fatty acids (EPA+DHA from fish oil), and nucleotides shown to reduce complications in major elective surgery patients³⁻¹¹

Consistent outcomes in over **80 publications** in major elective surgeries, including:
Upper GI, Lower GI, Cardiac, Head and Neck, Bladder Cancer, Gyn-Oncology, Hip



Nutrition Information

Serving Size	IMPACT ADVANCED RECOVERY® Drink		IMPACT® Formula	IMPACT® Peptide 1.5 Formula
	Per 178 mL carton	Per 534 mL (3 cartons)	Per 1000 mL	Per 1000 mL
Supplemental L-arginine (g)	4.2	12.6	12.5	18.7
EPA + DHA (g)	1.1	3.3	1.7	4.9
Nucleotides (g)	0.43	1.3	1.2	1.8
Calories (kcal)	200	600	1,000	1,500
Protein (g)	18 (35% of total kcal)	54 (35% of total kcal)	56 (22% of total kcal)	94 (25% of total kcal)

Ordering Information

PRODUCT	PRODUCT CODE	NDC FORMAT NUMBER	CASE UPC (GTIN)	PACKAGING
IMPACT® Unflavored	35810000	43900-0358-10	10043900358106	24-250 mL cartons/case
IMPACT® UltraPak® System	35810800	43900-0358-18	10043900358182	6-1000 mL bags/case
IMPACT ADVANCED RECOVERY® Vanilla	4390099291	43900-0992-90	00043900992914	15-178 mL cartons/case
IMPACT® Peptide 1.5 Unflavored	4390097400	43900-0973-99	10043900974009	24-250 mL cartons/case
IMPACT® Peptide 1.5 UltraPak® System	4390097371	43900-0973-70	10043900973712	6-1000 mL bags/case

NDC Formatted Numbers are not actual National Drug Codes (NDC). They are product codes adjusted according to standard industry practice to meet the format requirements of certain suppliers and payers. Nestlé HealthCare Nutrition submits product information including various product codes to the compendia including First Data Bank, RedBook and Medispan but cannot confirm that the NDC Formatted Numbers submitted have been published by the compendia.

References 1. Mauskopf JA et al. *WJSO* 2012;10:136. 2. Braga M et al. *Nutrition* 2005;21:1078-1086. 3. Braga M et al. *Surgery* 2002;132(5):805-814. 4. Braga M et al. *Arch Surg* 2002;137:174-180. 5. Drover JW et al. *J Am Coll Surg* 2011;212(3):385-399. 6. Ferreras N et al. *Clin Nutr* 2005;24:55-65. 7. Rowan NR et al. *Oral Onc* 2016;54:42-46. 8. Waitzberg DL et al. *World J Surg* 2006;30:1592-1604. 9. Chapman JS et al. *Gynecologic Oncology* 2015;137:523-528. 10. Tepaske R et al. *JPEN* 2007;31(3):173-180. 11. Bertrand J et al. *World J Urol* 2014;32:233-237.

USE UNDER MEDICAL SUPERVISION. NOT INDICATED WHEN IMMUNE SUPPRESSION IS DESIRED.

www.NestleHealthScience.us • 1-800-422-ASK2 (2752)

All trademarks are owned by Société des Produits Nestlé S.A., Vevey, Switzerland.
©2016 Nestlé. All rights reserved.

IPCT-12017-0119

